PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21864683-4 2011 Its affinity for recombinant B1 and B2 receptors is very low, as assessed by the binding competition of [3H]Lys-des-Arg9-BK and [3H]BK, respectively, but Met-Lys-BK-Ser-Ser effectively displaced a fraction of [3H]enalaprilat binding to recombinant ACE. Tritium 129-131 kininogen 1 Homo sapiens 132-134 21864683-4 2011 Its affinity for recombinant B1 and B2 receptors is very low, as assessed by the binding competition of [3H]Lys-des-Arg9-BK and [3H]BK, respectively, but Met-Lys-BK-Ser-Ser effectively displaced a fraction of [3H]enalaprilat binding to recombinant ACE. Tritium 129-131 kininogen 1 Homo sapiens 132-134 21864683-4 2011 Its affinity for recombinant B1 and B2 receptors is very low, as assessed by the binding competition of [3H]Lys-des-Arg9-BK and [3H]BK, respectively, but Met-Lys-BK-Ser-Ser effectively displaced a fraction of [3H]enalaprilat binding to recombinant ACE. Tritium 129-131 kininogen 1 Homo sapiens 132-134 21756898-5 2011 Anti-myc antibodies, conjugated or not with secondary antibodies optionally coupled to Qdot nanomaterials, were transported into early endosome autoantigen 1-, and beta-arrestin-positive vesicles in bradykinin-stimulated intact cells expressing receptors encoded by myc-B(2)R. Antibody-conjugated cargoes progressed into late-endosomes-lysosomes within 3h without evidence of autophagy. Tritium 353-355 kininogen 1 Homo sapiens 199-209 21864683-4 2011 Its affinity for recombinant B1 and B2 receptors is very low, as assessed by the binding competition of [3H]Lys-des-Arg9-BK and [3H]BK, respectively, but Met-Lys-BK-Ser-Ser effectively displaced a fraction of [3H]enalaprilat binding to recombinant ACE. Tritium 105-107 kininogen 1 Homo sapiens 121-123 21864683-4 2011 Its affinity for recombinant B1 and B2 receptors is very low, as assessed by the binding competition of [3H]Lys-des-Arg9-BK and [3H]BK, respectively, but Met-Lys-BK-Ser-Ser effectively displaced a fraction of [3H]enalaprilat binding to recombinant ACE. Tritium 129-131 kininogen 1 Homo sapiens 132-134 18355801-5 2008 Aspirin reduces the apparent affinity of the receptor for [3H]-bradykinin by accelerating the dissociation rate of [3H]-bradykinin-receptor complexes. Tritium 59-61 kininogen 1 Homo sapiens 63-73 20050188-4 2009 KEY RESULTS: [3H]-BK saturation studies indicated receptor density (Bmax) and K(d) values of 121,550 sites per cell and 1.14 nM respectively. Tritium 14-16 kininogen 1 Homo sapiens 18-20 18355801-6 2008 In addition, aspirin reduces the capacity of unlabeled bradykinin or the B2 receptor antagonist icatibant to destabilize pre-formed [3H]-bradykinin-receptor complexes. Tritium 133-135 kininogen 1 Homo sapiens 137-147 20946124-5 2011 KEY RESULTS: Density of [3H]-BK binding sites was higher (13-30-fold) and BK evoked a greater (48-fold) IP production, in human than in rat chondrocytes. Tritium 25-27 kininogen 1 Homo sapiens 29-31 20469905-0 2010 Evidence for a quasi-equilibrium distribution of states for bradykinin [M + 3H]3+ ions in the gas phase. Tritium 76-78 kininogen 1 Homo sapiens 60-70 20469905-1 2010 Multidimensional ion mobility spectrometry coupled with mass spectrometry (IMS-IMS-MS) techniques are used to select and activate six different gas-phase conformations of bradykinin [M + 3H](3+) ions. Tritium 187-189 kininogen 1 Homo sapiens 171-181 18355801-5 2008 Aspirin reduces the apparent affinity of the receptor for [3H]-bradykinin by accelerating the dissociation rate of [3H]-bradykinin-receptor complexes. Tritium 59-61 kininogen 1 Homo sapiens 120-130 18355801-6 2008 In addition, aspirin reduces the capacity of unlabeled bradykinin or the B2 receptor antagonist icatibant to destabilize pre-formed [3H]-bradykinin-receptor complexes. Tritium 133-135 kininogen 1 Homo sapiens 55-65 15573401-5 2005 Inhibition of PI3-K by LY294002 attenuated BK-induced Akt and p42/p44 MAPK phosphorylation and [3H]thymidine incorporation, but had no effect on EGFR phosphorylation, suggesting that EGFR may be an upstream component of PI3-K/Akt and MAPK in these responses. Tritium 96-98 kininogen 1 Homo sapiens 43-45 15573401-4 2005 We initially observed that BK- and EGF-dependent activation of Src, EGFR, Akt, and p42/p44 MAPK and [3H]thymidine incorporation were mediated by Src and EGFR, because the Src inhibitor PP1 and EGFR kinase inhibitor AG1478 abrogated BK- and EGF-dependent effects. Tritium 101-103 kininogen 1 Homo sapiens 27-29 16497154-6 2006 The receptor binds [3H]Lys-des-Arg9-bradykinin in a saturable manner (K(d) 0.36 nM) and exhibits a pharmacological profile similar to that of human B(1)R. Tritium 20-22 kininogen 1 Homo sapiens 36-46 15573401-4 2005 We initially observed that BK- and EGF-dependent activation of Src, EGFR, Akt, and p42/p44 MAPK and [3H]thymidine incorporation were mediated by Src and EGFR, because the Src inhibitor PP1 and EGFR kinase inhibitor AG1478 abrogated BK- and EGF-dependent effects. Tritium 101-103 kininogen 1 Homo sapiens 232-234 15573401-7 2005 Pretreatment with U0126 (a MEK1/2 inhibitor) attenuated the p42/p44 MAPK phosphorylation and [3H]thymidine incorporation stimulated by BK, but had no effect on Akt activation. Tritium 94-96 kininogen 1 Homo sapiens 135-137 12970081-1 2003 Binding affinity at the [3H]-BK binding site and activity as inositol phosphate (IP) production by the peptide bradykinin (BK) and the nonpeptide FR190997 were studied at wild-type or point-mutated human B2 receptors (hB2R) expressed in CHO cells. Tritium 25-27 kininogen 1 Homo sapiens 29-31 14751540-5 2004 BK stimulated [3H]thymidine incorporation and p42/p44 MAPK phosphorylation in a time- and concentration-dependent manner. Tritium 15-17 kininogen 1 Homo sapiens 0-2 14757160-5 2004 The affinities in competing for [3H]-BK binding and in blocking the BK-induced IP production by the non-peptide antagonists LF16-0687 and FR173657 at the wild type and mutant receptors were analysed. Tritium 33-35 kininogen 1 Homo sapiens 37-39 10209009-8 1999 Ramiprilat also decreased [3H]bradykinin binding to CR membranes when applied either before or after bradykinin stimulation. Tritium 27-29 kininogen 1 Homo sapiens 30-40 10689670-1 2000 The gas phase H/D exchange reactions of bradykinin (M + 3H)3+ ions with D2O and DI were monitored in a quadrupole ion trap mass spectrometer. Tritium 56-58 kininogen 1 Homo sapiens 40-50 10689670-2 2000 The H/D exchange kinetics of both chemical probes (D2O and DI) indicate the presence of two noninterconverting reactive gas phase ion populations of bradykinin (M + 3H)3+ at room temperature. Tritium 165-167 kininogen 1 Homo sapiens 149-159 12623967-6 2003 Tissue kallikrein competed for [3H]bradykinin binding to B2R-GFP only at 1 micromol/L. Tritium 32-34 kininogen 1 Homo sapiens 35-45 11104833-8 2000 In radioligand binding experiments, MEN 11270 and Icatibant displaced the [3H]bradykinin binding with pKi of 10.2 and 10.5 (Hill slope not different from unity), respectively. Tritium 75-77 kininogen 1 Homo sapiens 78-88 11104833-9 2000 The non-peptide ligands displaced the [3H]bradykinin binding with similar affinity, their pKi being 8.7 and 8.6 for FR173657 and FR190997, respectively (both Hill slopes <1). Tritium 39-41 kininogen 1 Homo sapiens 42-52 9754910-3 1998 Analysis of specific [3H]-bradykinin binding revealed that IFNgamma-treated cells had a two- to threefold increase in bradykinin receptor number compared to the controls with no effect on receptor affinity. Tritium 22-24 kininogen 1 Homo sapiens 26-36 9446564-2 1998 Incubation of [3H]BK at 37 degrees C with cells expressing wild type B2KR resulted in pronounced and rapid ligand internalization ( approximately 80% after 10 min). Tritium 15-17 kininogen 1 Homo sapiens 18-20 9555059-5 1998 The observation that ethanol could significantly reduce [3H]PtdOH formation in myoblasts stimulated with BK and thrombin indicates that stimulation of PLD has a major role. Tritium 57-59 kininogen 1 Homo sapiens 105-107 9555059-7 1998 In addition, BK and thrombin appear able to activate DAG kinase at early times of incubation and also this pathway may contribute to determine the increase in [3H]PtdOH levels. Tritium 160-162 kininogen 1 Homo sapiens 13-15 9446564-7 1998 Truncation of the B2KR up to Lys315 almost completely abolished internalization of [3H]BK (10% after 10 min). Tritium 84-86 kininogen 1 Homo sapiens 87-89 9446564-8 1998 This additional reduction is apparently not caused by the loss of the potential palmitoylation site at Cys324, since a B2KR with a point mutation of Cys324 to Ala internalized [3H]BK as rapidly as the wild type B2KR. Tritium 177-179 kininogen 1 Homo sapiens 180-182 9421294-5 1997 [3H]-BK, a full agonist labelled ligand, was used to demonstrate a single binding site giving a Kd value of 0.51+/-0.02 nM and a Bmax of 24+/-1 fmol mg(-1) protein. Tritium 1-4 kininogen 1 Homo sapiens 5-7 9651119-0 1998 Characterization of bradykinin receptors in human lung fibroblasts using the binding of 3[H][Des-Arg10,Leu9]kallidin and [3H]NPC17731. Tritium 122-124 kininogen 1 Homo sapiens 20-30 9276139-6 1997 FR173657 inhibited [3H]BK binding to A431, W138, and IMR90 cell lines of human origin with IC50 values of 2.0 x 10(-9), 2.3 x 10(-9), and 1.7 x 10(-9) M, respectively. Tritium 20-22 kininogen 1 Homo sapiens 23-25 9311664-2 1997 This compound competitively displaced [3H]bradykinin binding to bradykinin B2 receptors present in guinea-pig ileum membrane with an IC50 value of 6.6 X 10(-10) M. In isolated guinea-pig ileum preparations, it also antagonized bradykinin-induced contraction with a pA2 value of 9.3. Tritium 39-41 kininogen 1 Homo sapiens 42-52 9311664-2 1997 This compound competitively displaced [3H]bradykinin binding to bradykinin B2 receptors present in guinea-pig ileum membrane with an IC50 value of 6.6 X 10(-10) M. In isolated guinea-pig ileum preparations, it also antagonized bradykinin-induced contraction with a pA2 value of 9.3. Tritium 39-41 kininogen 1 Homo sapiens 64-74 9311664-2 1997 This compound competitively displaced [3H]bradykinin binding to bradykinin B2 receptors present in guinea-pig ileum membrane with an IC50 value of 6.6 X 10(-10) M. In isolated guinea-pig ileum preparations, it also antagonized bradykinin-induced contraction with a pA2 value of 9.3. Tritium 39-41 kininogen 1 Homo sapiens 64-74 9311664-3 1997 In human lung fibroblast IMR-90 cells, FR167344 displaced [3H]bradykinin binding to human bradykinin B2 receptors with an IC50 value of 1.3 X 10(-8) M, but not [3H]des-Arg10-kallidin binding to human bradykinin B1 receptors. Tritium 59-61 kininogen 1 Homo sapiens 62-72 9228537-7 1997 Competitive binding studies showed displacement of [3H]-bradykinin by HOE 140, but not by the ligands for the bradykinin B1-receptor, des-Arg10-kallidin and [Leu8]-des-Arg9-bradykinin. Tritium 52-54 kininogen 1 Homo sapiens 56-66 9332450-3 1997 PGE2 (10 nM) produced a concentration-dependent increase in [3H]-BK specific binding after a lag time of 24 h with a threshold at 0.1 nM. Tritium 61-63 kininogen 1 Homo sapiens 65-67 9208130-7 1997 Bradykinin (BK) induced a maximal 1.95 +/- 0.24 fold (n = 17) and 2.51 +/- 0.29 fold (n = 26) stimulation of [3H]-IPs accumulation in normal, primary (P-CEPI) and SV40-immortalized (CEPI-17-CL4) cells, respectively. Tritium 110-112 kininogen 1 Homo sapiens 0-10 9208130-7 1997 Bradykinin (BK) induced a maximal 1.95 +/- 0.24 fold (n = 17) and 2.51 +/- 0.29 fold (n = 26) stimulation of [3H]-IPs accumulation in normal, primary (P-CEPI) and SV40-immortalized (CEPI-17-CL4) cells, respectively. Tritium 110-112 kininogen 1 Homo sapiens 12-14 8939910-3 1996 The Ser20 and Ser277 single mutants and the Ser20/Ser277 double mutant bound [3H]BK and the antagonist [3H]NPC17731 with pharmacological profiles identical to the wild-type B2 receptor. Tritium 78-80 kininogen 1 Homo sapiens 81-83 8922733-10 1996 This is the first characterization of [3H]-des-Arg10-KD binding to include both kinetic and equilibrium data, and demonstrates that [3H]-des-Arg10-KD has a high affinity for human B1 bradykinin receptors and is sufficiently selective to be used as a radioligand for B1 receptors in human cells or tissues expressing an excess of B2 BK receptors. Tritium 39-41 kininogen 1 Homo sapiens 183-193 8922733-10 1996 This is the first characterization of [3H]-des-Arg10-KD binding to include both kinetic and equilibrium data, and demonstrates that [3H]-des-Arg10-KD has a high affinity for human B1 bradykinin receptors and is sufficiently selective to be used as a radioligand for B1 receptors in human cells or tissues expressing an excess of B2 BK receptors. Tritium 133-135 kininogen 1 Homo sapiens 183-193 8853439-2 1996 [3H]BK bound specifically in a manner consistent with a single high-affinity site. Tritium 1-3 kininogen 1 Homo sapiens 4-6 7498312-1 1995 High affinity [3H]bradykinin binding sites have been identified in human skin cryosections by in vitro autoradiography. Tritium 15-17 kininogen 1 Homo sapiens 18-28 8833191-10 1996 (3H)BK binding and AlF(4)--induced but not A23187- or ionomycin-induced PI hydrolysis were increased, indicating that the site of action of long-term ET-1 treatment was the BK receptor and G protein; Scatchard analysis showed an increase in Bmax but no effect on Kd. Tritium 1-3 kininogen 1 Homo sapiens 4-6 8764214-2 1996 Bradykinin induced a significant increase in [3H]glycoconjugate secretion in a dose-dependent manner from isolated glands, which was significantly inhibited by D-Arg-(Hyp3, Thi5,8, D-Phe7)-bradykinin (the B2-receptor antagonist), whereas Des-Arg9-(Leu8)-bradykinin (B1-receptor antagonist) or indomethacin did not significantly alter it. Tritium 46-48 kininogen 1 Homo sapiens 0-10 8764214-2 1996 Bradykinin induced a significant increase in [3H]glycoconjugate secretion in a dose-dependent manner from isolated glands, which was significantly inhibited by D-Arg-(Hyp3, Thi5,8, D-Phe7)-bradykinin (the B2-receptor antagonist), whereas Des-Arg9-(Leu8)-bradykinin (B1-receptor antagonist) or indomethacin did not significantly alter it. Tritium 46-48 kininogen 1 Homo sapiens 189-199 9213428-1 1996 The [(3)H]inositol incorporation into the membrane fraction of A-431 human epidermoid carcinoma cells was markedly increased by stimulation of the cells with either epidermal growth factor (EGF), ATP, bradykinin, or a calcium ionophore A23187 in the presence of 1 mM extracellular calcium ions; most incorporated [(3)H]inositol was found to have accumulated as phosphatidylinositol (PI). Tritium 5-9 kininogen 1 Homo sapiens 201-211 7498312-2 1995 Equilibrium binding studies were performed with increasing concentrations of [3H]bradykinin for 120 min in the presence of protease inhibitors at 4 degrees C. In saturation experiments a single class of high affinity binding sites was identified with a dissociation constant Kd of 1.2 +/- 0.8 nM (mean +/- S.E.M., n = 3) and a maximal binding capacity Bmax of 33 +/- 8 fmol [3H]bradykinin specifically bound/mg protein (mean +/- S.E.M., n = 3). Tritium 78-80 kininogen 1 Homo sapiens 81-91 7498312-2 1995 Equilibrium binding studies were performed with increasing concentrations of [3H]bradykinin for 120 min in the presence of protease inhibitors at 4 degrees C. In saturation experiments a single class of high affinity binding sites was identified with a dissociation constant Kd of 1.2 +/- 0.8 nM (mean +/- S.E.M., n = 3) and a maximal binding capacity Bmax of 33 +/- 8 fmol [3H]bradykinin specifically bound/mg protein (mean +/- S.E.M., n = 3). Tritium 375-377 kininogen 1 Homo sapiens 81-91 8588976-2 1995 In [3H]myristate-labelled endometrial stromal cells, bradykinin and tetradecanoylphorbol acetate (TPA) mediated activation of phospholipase D (PLD) as measured by the accumulation of [3H]phosphatidylbutanol ([3H]PtdBut). Tritium 4-6 kininogen 1 Homo sapiens 53-63 8588976-4 1995 Bradykinin induced a dose-dependent (EC50 0.11 nM) [3H]PtdBut accumulation at concentrations at which it stimulated DNA synthesis. Tritium 52-54 kininogen 1 Homo sapiens 0-10 8588976-5 1995 In [3H]inositol-labelled cells, bradykinin evoked a rapid increase in inositol phosphates which preceded the increase in [3H]PtdBut formation. Tritium 4-6 kininogen 1 Homo sapiens 32-42 8588976-5 1995 In [3H]inositol-labelled cells, bradykinin evoked a rapid increase in inositol phosphates which preceded the increase in [3H]PtdBut formation. Tritium 122-124 kininogen 1 Homo sapiens 32-42 8588976-7 1995 Staurosporine, an inhibitor of protein kinase C, strongly inhibited (IC50 96 nM) TPA-induced [3H]PtdBut formation, but bradykinin-stimulated [3H]PtdBut accumulation was only partially inhibited (IC50 65 microM). Tritium 142-144 kininogen 1 Homo sapiens 119-129 8043027-1 1994 Bradykinin (BK) evoked [3H]noradrenaline ([3H]NA) release from the human neuroblastoma SH-SY5Y and this was enhanced by pre-treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA) for 8 min. Tritium 23-27 kininogen 1 Homo sapiens 0-10 7620702-27 1995 At this point accumulations were dose-related with a potency similar to that of sustained Ins(1,4,5)P3 accumulation.However, bradykinin produced a minor accumulation of [3H]-InsPs, maximal by 1 min. Tritium 170-172 kininogen 1 Homo sapiens 125-135 8619926-6 1995 As phosphatidate, the product of phospholipase D pathway, may mediate cell proliferation, the effect of 17 beta-oestradiol on bradykinin-evoked phospholipase D activity assayed as accumulation of [3H]phosphatidylbutanol ([3H]PtdBut) was examined in [3H]myristic acid-labelled primary cultures of human endometrial stromal cells. Tritium 197-199 kininogen 1 Homo sapiens 126-136 8619926-6 1995 As phosphatidate, the product of phospholipase D pathway, may mediate cell proliferation, the effect of 17 beta-oestradiol on bradykinin-evoked phospholipase D activity assayed as accumulation of [3H]phosphatidylbutanol ([3H]PtdBut) was examined in [3H]myristic acid-labelled primary cultures of human endometrial stromal cells. Tritium 222-224 kininogen 1 Homo sapiens 126-136 8619926-7 1995 Bradykinin induced a rapid accumulation of [3H]PtdBut in a time-dependent manner, indicating phospholipase D activation. Tritium 44-46 kininogen 1 Homo sapiens 0-10 7772029-9 1995 An accumulation of [3H]PEth was measured in the plasma-membrane (PM)-enriched fractions of both HeLa and 3T3 Li cells after incubation with PMA and bradykinin respectively. Tritium 20-22 kininogen 1 Homo sapiens 148-158 7741756-3 1995 In contrast, bradykinin (1 microM), 5-hydroxytryptamine (5-HT) (0.1 mM) and carbachol (1 mM) produced only a small (< 1% of the response to 1 mM histamine) effect on [3H]inositol phosphate accumulation in these cells. Tritium 170-172 kininogen 1 Homo sapiens 13-23 7861149-8 1995 It is proposed, therefore, that Ca2+ release from Ins (1,4,5)P3-sensitive stores is a major trigger of methacholine- and bradykinin-evoked [3H]NA release in SH-SY5Y cells. Tritium 140-142 kininogen 1 Homo sapiens 121-131 8063797-5 1994 The cloned B1 bradykinin receptor expressed in mammalian cells exhibits high affinity binding for 3H-labeled [des-Arg10]kallidin and low affinity for bradykinin. Tritium 98-100 kininogen 1 Homo sapiens 14-24 8043027-1 1994 Bradykinin (BK) evoked [3H]noradrenaline ([3H]NA) release from the human neuroblastoma SH-SY5Y and this was enhanced by pre-treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA) for 8 min. Tritium 23-27 kininogen 1 Homo sapiens 12-14 8043027-6 1994 Although pre-treatment of SH-SY5Y cells with TPA enhanced BK-evoked [3H]NA release, the elevation of intracellular calcium [Ca2+]; was decreased by about 50%. Tritium 69-71 kininogen 1 Homo sapiens 58-60 8043027-7 1994 BK-evoked release of [3H]NA in cells not pre-treated with phorbol ester was only 23% dependent on extracellular calcium. Tritium 22-24 kininogen 1 Homo sapiens 0-2 8043027-10 1994 The results of this study showed that BK, acting at B2-receptors, activated [3H]NA release in SH-SY5Y. Tritium 77-79 kininogen 1 Homo sapiens 38-40 8062861-9 1994 BK and BK-B2 receptor agonists as well as thrombin, but not BK-B1 receptor agonists, also significantly increased [3H] release in human PDL-cells prelabelled with [3H]-arachidonic acid, indicating that BK and thrombin stimulate prostanoid biosynthesis, at least partly, due to activation of phospholipase A2. Tritium 115-117 kininogen 1 Homo sapiens 0-2 8062861-9 1994 BK and BK-B2 receptor agonists as well as thrombin, but not BK-B1 receptor agonists, also significantly increased [3H] release in human PDL-cells prelabelled with [3H]-arachidonic acid, indicating that BK and thrombin stimulate prostanoid biosynthesis, at least partly, due to activation of phospholipase A2. Tritium 115-117 kininogen 1 Homo sapiens 7-9 8062861-9 1994 BK and BK-B2 receptor agonists as well as thrombin, but not BK-B1 receptor agonists, also significantly increased [3H] release in human PDL-cells prelabelled with [3H]-arachidonic acid, indicating that BK and thrombin stimulate prostanoid biosynthesis, at least partly, due to activation of phospholipase A2. Tritium 164-166 kininogen 1 Homo sapiens 0-2 8062861-9 1994 BK and BK-B2 receptor agonists as well as thrombin, but not BK-B1 receptor agonists, also significantly increased [3H] release in human PDL-cells prelabelled with [3H]-arachidonic acid, indicating that BK and thrombin stimulate prostanoid biosynthesis, at least partly, due to activation of phospholipase A2. Tritium 164-166 kininogen 1 Homo sapiens 7-9 8176221-6 1994 BK also activated a phospholipase D (PLD) to cleave phosphatidylcholine (PC), because it caused an increase in phosphatidic acid (PA) content and a sustained DAG formation, which both were inhibited by ethanol in [3H]myristic acid-labeled cells. Tritium 214-216 kininogen 1 Homo sapiens 0-2 8197121-2 1994 WIN 64338 inhibits [3H]-bradykinin binding to the bradykinin B2 receptor on human IMR-90 cells with a binding inhibition constant (Ki) of 64 +/- 8 nM and demonstrates competitive inhibition of bradykinin-stimulated 45Ca2+ efflux from IMR-90 cells (pA2 = 7.1). Tritium 20-22 kininogen 1 Homo sapiens 24-34 8197121-2 1994 WIN 64338 inhibits [3H]-bradykinin binding to the bradykinin B2 receptor on human IMR-90 cells with a binding inhibition constant (Ki) of 64 +/- 8 nM and demonstrates competitive inhibition of bradykinin-stimulated 45Ca2+ efflux from IMR-90 cells (pA2 = 7.1). Tritium 20-22 kininogen 1 Homo sapiens 50-60 8032609-4 1994 The binding of [3H]-bradykinin to healthy lung membrane is time-dependent and saturable with a KD value of 1.08 +/- 08 nM and a Bmax value of 46.1 +/- 3.1 fmol mg-1 protein (n = 10). Tritium 16-18 kininogen 1 Homo sapiens 20-30 8032609-8 1994 In both healthy and squamous-carcinoma preparations, bradykinin analogues displace [3H]-bradykinin binding with the following relative order of potency: Hoe 140 > bradykinin > kallidin > D-Arg0[Hyp3,D-Phe7]bradykinin >>> des-Arg9-bradykinin. Tritium 84-86 kininogen 1 Homo sapiens 53-63 8032609-8 1994 In both healthy and squamous-carcinoma preparations, bradykinin analogues displace [3H]-bradykinin binding with the following relative order of potency: Hoe 140 > bradykinin > kallidin > D-Arg0[Hyp3,D-Phe7]bradykinin >>> des-Arg9-bradykinin. Tritium 84-86 kininogen 1 Homo sapiens 88-98 8032609-8 1994 In both healthy and squamous-carcinoma preparations, bradykinin analogues displace [3H]-bradykinin binding with the following relative order of potency: Hoe 140 > bradykinin > kallidin > D-Arg0[Hyp3,D-Phe7]bradykinin >>> des-Arg9-bradykinin. Tritium 84-86 kininogen 1 Homo sapiens 88-98 8032609-8 1994 In both healthy and squamous-carcinoma preparations, bradykinin analogues displace [3H]-bradykinin binding with the following relative order of potency: Hoe 140 > bradykinin > kallidin > D-Arg0[Hyp3,D-Phe7]bradykinin >>> des-Arg9-bradykinin. Tritium 84-86 kininogen 1 Homo sapiens 88-98 8032609-8 1994 In both healthy and squamous-carcinoma preparations, bradykinin analogues displace [3H]-bradykinin binding with the following relative order of potency: Hoe 140 > bradykinin > kallidin > D-Arg0[Hyp3,D-Phe7]bradykinin >>> des-Arg9-bradykinin. Tritium 84-86 kininogen 1 Homo sapiens 88-98 8117696-1 1994 D-Arg0[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (HOE-140) is a potent (Ki = 0.11 nM) inhibitor of [3H]bradykinin binding to bradykinin B2 receptors found on human IMR-90 fetal lung fibroblasts. Tritium 91-93 kininogen 1 Homo sapiens 29-39 8117696-1 1994 D-Arg0[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (HOE-140) is a potent (Ki = 0.11 nM) inhibitor of [3H]bradykinin binding to bradykinin B2 receptors found on human IMR-90 fetal lung fibroblasts. Tritium 91-93 kininogen 1 Homo sapiens 94-104 8117696-1 1994 D-Arg0[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (HOE-140) is a potent (Ki = 0.11 nM) inhibitor of [3H]bradykinin binding to bradykinin B2 receptors found on human IMR-90 fetal lung fibroblasts. Tritium 91-93 kininogen 1 Homo sapiens 94-104 8397092-2 1993 Histamine (EC50 6.5 microM), bradykinin (EC50 9.7 nM), carbachol (EC50 10 microM), substance P and NaF all produced concentration dependent [3H]inositol phosphate formation in these cells. Tritium 141-143 kininogen 1 Homo sapiens 29-39 1328896-2 1992 Addition of bradykinin to D384 cells resulted in a concentration-dependent (10(-11)-10(-6) M) increase in the accumulation of [3H]inositol phosphates and a similar concentration-dependent transient increase in specific [3H]beta-phorbol-12,13-dibutyrate binding which is indicative of translocation of protein kinase C from the cytosol to the membrane. Tritium 127-129 kininogen 1 Homo sapiens 12-22 1335417-1 1992 [3H]Bradykinin binds to intact human IMR-90 fetal lung fibroblasts in a time and dose-dependent manner. Tritium 1-3 kininogen 1 Homo sapiens 4-14 1335417-2 1992 Binding equilibrium was attained by 120 minutes at 4 degrees C. [3H]Bradykinin binding was saturable; Scatchard analysis of saturation binding data demonstrated a single binding site having a KD = 1.8 +/- 0.2 nM and a receptor concentration of 17.4 +/- 4.0 fmol/10(5) cells. Tritium 65-67 kininogen 1 Homo sapiens 68-78 1333454-2 1992 [3H]BK binds to a single class of receptors on A431 cells in a saturable and reversible manner. Tritium 1-3 kininogen 1 Homo sapiens 4-6 1737988-1 1992 In cultured dorsal root ganglion (DRG) neurons prelabeled with [3H]arachidonic acid [( 3H]AA), bradykinin (BK) stimulation resulted in increased levels of radioactive diacylglycerol, monoacylglycerol, and free AA. Tritium 64-66 kininogen 1 Homo sapiens 95-105 1322819-3 1992 Radioligand binding studies reveal a population of [3H]bradykinin binding sites whose affinity correlates with this B2 receptor"s biologic activity, with a KD of 2.5 nM. Tritium 52-54 kininogen 1 Homo sapiens 55-65 1322819-4 1992 As IMR90 cells reach 60% of their defined life span in culture, they spontaneously induce expression of a second site of lower affinity, with half-maximal binding of [3H]bradykinin at 44 nM. Tritium 167-169 kininogen 1 Homo sapiens 170-180 1737988-1 1992 In cultured dorsal root ganglion (DRG) neurons prelabeled with [3H]arachidonic acid [( 3H]AA), bradykinin (BK) stimulation resulted in increased levels of radioactive diacylglycerol, monoacylglycerol, and free AA. Tritium 64-66 kininogen 1 Homo sapiens 107-109 1737988-5 1992 When DRG cultures were labeled with [3H]stearic acid, treatment with BK increased the amount of label in diacylglycerol and free stearic acid, but not in monoacylglycerol. Tritium 36-39 kininogen 1 Homo sapiens 69-71 1309439-4 1992 Bradykinin also caused a dose-dependent decrease in cell growth and [3H]thymidine incorporation into DNA in breast fibroblasts. Tritium 69-71 kininogen 1 Homo sapiens 0-10 1318290-4 1992 Specificity of [3H]BK binding was confirmed by the ability of several BK peptide agonists and antagonists to inhibit binding in a dose dependent manner. Tritium 16-18 kininogen 1 Homo sapiens 19-21 1318290-4 1992 Specificity of [3H]BK binding was confirmed by the ability of several BK peptide agonists and antagonists to inhibit binding in a dose dependent manner. Tritium 16-18 kininogen 1 Homo sapiens 70-72 1744575-2 1991 In human endometrial stromal cells, bombesin and bradykinin provoked an increase in intracellular free Ca2+ and in labelled inositol phosphates when pre-incubated with [3H]myoinositol. Tritium 169-171 kininogen 1 Homo sapiens 49-59 1309881-4 1992 We performed [3H]bradykinin binding studies in intact human synovial tissue and in cultured human synovial cells. Tritium 14-16 kininogen 1 Homo sapiens 17-27 1309881-5 1992 Specific, saturable [3H]bradykinin binding sites in intact synovia were identified by autoradiographic localization and were present in much higher density in rheumatoid, than in osteoarthritis, synovia. Tritium 21-23 kininogen 1 Homo sapiens 24-34 1309881-7 1992 In matched experiments, IL-1 treatment enhanced specific [3H]bradykinin binding 1.5- to 2.0-fold above that observed in untreated cells. Tritium 58-60 kininogen 1 Homo sapiens 61-71 1309881-9 1992 The potencies of a series of kinin analogs and antagonists and unrelated peptides in displacing [3H]bradykinin from IL-1-treated cells correlated well with their abilities to induce prostanoid release. Tritium 97-99 kininogen 1 Homo sapiens 100-110 1993889-1 1991 In previous studies it has been shown that both bradykinin and histamine increase the formation of 3H-labeled inositol phosphates in adrenal chromaffin cells prelabelled with [3H]inositol and that both these agonists stimulate release of catecholamines by a mechanism dependent on extracellular calcium. Tritium 99-101 kininogen 1 Homo sapiens 48-58 1653071-5 1991 Prolonged treatment of HSWP cells with these agents also caused a 3 to 4 fold rise in cell surface [3H]-bradykinin binding. Tritium 100-102 kininogen 1 Homo sapiens 104-114 1653071-7 1991 In addition, cholera toxin and foreskolin increased [3H]-bradykinin binding in wildtype PC12 cells, but not in mutant PC12 cells with reduced cyclic AMP-dependent protein kinase type II activity. Tritium 53-55 kininogen 1 Homo sapiens 57-67 1993889-3 1991 Bradykinin increased the mass of Ins(1,3,4,5)P4 despite the failure in earlier studies with [3H]inositol-labelled cells to observe a bradykinin-mediated increase in content of [3H]InsP4. Tritium 177-179 kininogen 1 Homo sapiens 0-10 1993889-3 1991 Bradykinin increased the mass of Ins(1,3,4,5)P4 despite the failure in earlier studies with [3H]inositol-labelled cells to observe a bradykinin-mediated increase in content of [3H]InsP4. Tritium 177-179 kininogen 1 Homo sapiens 133-143 2037586-6 1991 Stimulation with BK resulted in the rapid and synchronous formation of [3H]choline and [3H]myristoyl-PA from the correspondingly prelabeled PC, indicative of phospholipase D (PLD) activity. Tritium 72-74 kininogen 1 Homo sapiens 17-19 2037586-6 1991 Stimulation with BK resulted in the rapid and synchronous formation of [3H]choline and [3H]myristoyl-PA from the correspondingly prelabeled PC, indicative of phospholipase D (PLD) activity. Tritium 88-90 kininogen 1 Homo sapiens 17-19 1653071-2 1991 The effect of bacterial toxins on bradykinin-triggered release of arachidonic acid was studied in serum-deprived human foreskin (HSWP) fibroblasts prelabelled with [3H]-arachidonic acid. Tritium 165-167 kininogen 1 Homo sapiens 34-44 2156727-2 1990 Both ligands competed with [3H]bradykinin binding in a dose-dependent fashion with potencies similar to bradykinin (BK) and Lys-BK. Tritium 28-30 kininogen 1 Homo sapiens 31-41 2280902-3 1990 Alkaline metals, barium (Ba2+), strontium (Sr2+) and other metal cations, manganese (Mn2+) or lanthanum (La3+), support BK-induced [3H]noradrenaline ([3H]NA) release. Tritium 151-153 kininogen 1 Homo sapiens 120-122 2174449-2 1990 Keratinocytes specifically bound [3H]bradykinin with high affinity (kd = 3.4 nM) and displayed 1.5 X 10(5) binding sites/cell. Tritium 34-36 kininogen 1 Homo sapiens 37-47 2280902-3 1990 Alkaline metals, barium (Ba2+), strontium (Sr2+) and other metal cations, manganese (Mn2+) or lanthanum (La3+), support BK-induced [3H]noradrenaline ([3H]NA) release. Tritium 132-134 kininogen 1 Homo sapiens 120-122 1963797-10 1990 Pretreatment for 10 min with TPA (but not the relatively inactive 4-methoxy TPA) or the non-phorbol protein kinase C stimulator mezerein potently inhibited bradykinin- and histamine-stimulated accumulation of total [3H]-inositol phosphate; inhibition of [3H]-inositol phosphate formation was also seen with 24 h TPA treatment. Tritium 216-219 kininogen 1 Homo sapiens 156-166 1697359-5 1990 The fate of receptor-bound [3H]BK was studied by the acetic acid "stripping technique" that completely removes surface-bound [3H]BK while leaving internalized material with the remaining cells. Tritium 28-30 kininogen 1 Homo sapiens 31-33 1697359-5 1990 The fate of receptor-bound [3H]BK was studied by the acetic acid "stripping technique" that completely removes surface-bound [3H]BK while leaving internalized material with the remaining cells. Tritium 126-128 kininogen 1 Homo sapiens 31-33 1697359-7 1990 High-performance liquid chromatography (HPLC) analysis of internalized 3H counts showed significant quantities of intact [3H]BK occurring in an intracellular compartment. Tritium 71-73 kininogen 1 Homo sapiens 125-127 1697359-7 1990 High-performance liquid chromatography (HPLC) analysis of internalized 3H counts showed significant quantities of intact [3H]BK occurring in an intracellular compartment. Tritium 122-124 kininogen 1 Homo sapiens 125-127 2545733-2 1989 Binding of 3H-bradykinin to these cells demonstrates a single receptor site with a Kd of 2.0 nM and a Bmax of 91 fmoles/mg protein. Tritium 11-13 kininogen 1 Homo sapiens 14-24 6470707-2 1984 Addition of [3H]bradykinin to extracts permitted calculation of recoveries and monitoring of chromatographic fractions. Tritium 13-15 kininogen 1 Homo sapiens 16-26 3146318-10 1988 Release of [3H]arachidonate by BK was deficient in NCL fibroblasts, suggesting that the primary defect in NCL could involve the deficiency of a specific phospholipase A2 activity. Tritium 12-14 kininogen 1 Homo sapiens 31-33 3771575-1 1986 Bradykinin stimulation of inositol polyphosphate production was followed using [3H]inositol-labeled porcine aortic endothelial cells grown in culture. Tritium 80-82 kininogen 1 Homo sapiens 0-10 2898111-2 1988 Stimulation of Flow 9000 cells, prelabelled with [3H]inositol, with the nonapeptide bradykinin (BK), or its analogues and fragments produced a differential accumulation of [3H]IP1. Tritium 50-52 kininogen 1 Homo sapiens 84-94 2898111-2 1988 Stimulation of Flow 9000 cells, prelabelled with [3H]inositol, with the nonapeptide bradykinin (BK), or its analogues and fragments produced a differential accumulation of [3H]IP1. Tritium 50-52 kininogen 1 Homo sapiens 96-98 2898111-5 1988 [3H]BK receptor binding studies showed that BK and [Des-Arg9]BK produced a concentration-dependent inhibition of [3H]BK binding with Ki values of 4.8 +/- 1.9 nM (n = 3) and 6.8 +/- 0.7 microM (n = 3) respectively. Tritium 1-3 kininogen 1 Homo sapiens 4-6 2898111-5 1988 [3H]BK receptor binding studies showed that BK and [Des-Arg9]BK produced a concentration-dependent inhibition of [3H]BK binding with Ki values of 4.8 +/- 1.9 nM (n = 3) and 6.8 +/- 0.7 microM (n = 3) respectively. Tritium 1-3 kininogen 1 Homo sapiens 44-46 2898111-5 1988 [3H]BK receptor binding studies showed that BK and [Des-Arg9]BK produced a concentration-dependent inhibition of [3H]BK binding with Ki values of 4.8 +/- 1.9 nM (n = 3) and 6.8 +/- 0.7 microM (n = 3) respectively. Tritium 1-3 kininogen 1 Homo sapiens 44-46 2898111-5 1988 [3H]BK receptor binding studies showed that BK and [Des-Arg9]BK produced a concentration-dependent inhibition of [3H]BK binding with Ki values of 4.8 +/- 1.9 nM (n = 3) and 6.8 +/- 0.7 microM (n = 3) respectively. Tritium 1-3 kininogen 1 Homo sapiens 44-46 6140924-7 1983 BK at 1.2 +/- 0.2 X 10(-6) M decreased the rate of [3H]-HGG hydrolysis by 50%. Tritium 52-54 kininogen 1 Homo sapiens 0-2 6564947-5 1984 Procedural losses are monitored by measuring the recovery of [3H]bradykinin and [3H]lysylbradykinin. Tritium 62-64 kininogen 1 Homo sapiens 65-75 6564947-6 1984 Simple methods for labeling of bradykinin and lysylbradykinin with tritium are also presented. Tritium 67-74 kininogen 1 Homo sapiens 31-41 6564947-7 1984 Recoveries of [3H]bradykinin and [3H]lysylbradykinin from biological material ranged between 77 and 91%. Tritium 15-17 kininogen 1 Homo sapiens 18-28 6146639-2 1984 Incubation of cells with 1 microM BK for 5 min at 37 degrees C led to a marked reduction (75-90%) in BK-induced PGI2 release and in total number of [3H]BK-binding sites with no change in dissociation constant (6.1 and 7.6 nM for control and BK-treated cells, respectively). Tritium 149-151 kininogen 1 Homo sapiens 34-36 6141950-1 1984 Bradykinin stimulates [3H]thymidine incorporation and DNA synthesis in resting, serum-deprived NIL8 hamster cells. Tritium 23-25 kininogen 1 Homo sapiens 0-10 6141950-3 1984 Other kinin peptides including lys-bradykinin (kallidin) and met-lys-bradykinin also stimulate [3H]thymidine incorporation in the NIL8 cells, whereas desarg9-bradykinin is without effect, suggesting action of the kinin peptides through type B2 receptors. Tritium 96-98 kininogen 1 Homo sapiens 35-45 6141950-3 1984 Other kinin peptides including lys-bradykinin (kallidin) and met-lys-bradykinin also stimulate [3H]thymidine incorporation in the NIL8 cells, whereas desarg9-bradykinin is without effect, suggesting action of the kinin peptides through type B2 receptors. Tritium 96-98 kininogen 1 Homo sapiens 69-79 6141950-3 1984 Other kinin peptides including lys-bradykinin (kallidin) and met-lys-bradykinin also stimulate [3H]thymidine incorporation in the NIL8 cells, whereas desarg9-bradykinin is without effect, suggesting action of the kinin peptides through type B2 receptors. Tritium 96-98 kininogen 1 Homo sapiens 69-79 30028131-2 2018 At elevated solution temperatures, we observe a slow protonation reaction, i.e., [BK+2H]2++H+ [BK+3H]3+, that is regulated by trans cis isomerization of Arg1-Pro2, resulting in the Arg1- cis-Pro2- cis-Pro3-Gly4-Phe5-Ser6- cis-Pro7-Phe8-Arg9 (all- cis) configuration. Tritium 100-102 kininogen 1 Homo sapiens 82-84 6135711-3 1983 During incubation with intact fibroblasts, intact [3H]bradykinin was lost much more rapidly at 37 degrees than at 4 degrees C as determined by bioassay, high-performance liquid chromatography, and ion-exchange chromatography, and is likely to be degraded. Tritium 51-53 kininogen 1 Homo sapiens 54-64 6135711-8 1983 The relative potencies of bradykinin analogues and unrelated peptides in competing for [3H]bradykinin binding indicated a specificity of the binding sites consistent with that of a B2 type receptor. Tritium 88-90 kininogen 1 Homo sapiens 26-36 6135711-8 1983 The relative potencies of bradykinin analogues and unrelated peptides in competing for [3H]bradykinin binding indicated a specificity of the binding sites consistent with that of a B2 type receptor. Tritium 88-90 kininogen 1 Homo sapiens 91-101 6135711-9 1983 Potencies of the peptides in displacing [3H]bradykinin correlated with their abilities to release prostacyclin, determined as its metabolite 6-keto-PGF1 alpha. Tritium 41-43 kininogen 1 Homo sapiens 44-54 7250322-1 1981 In the isolated lapine kidney perfused with tyrode solution and prelabeled with [3H] norepinephrine, bradykinin (10 ng/ml) decreased the overflow of tritium elicited by sympathetic nerve stimulation both in the presence and absence of indomethacin. Tritium 149-156 kininogen 1 Homo sapiens 101-111 6113593-1 1981 [3H]Bradykinin binds to membranes from a variety of mammalian tissues in a saturable fashion with a dissociation constant of about 5 nM. Tritium 1-3 kininogen 1 Homo sapiens 4-14 225265-1 1979 Bradykinin induces an increment in intracellular cyclic AMP concentrations of human synovial fibroblasts and evokes the release of [3H]arachidonic acid and [3H]-E prostaglandins from human synovial fibroblasts pre-labeled in their phospholipids. Tritium 132-134 kininogen 1 Homo sapiens 0-10 30028131-2 2018 At elevated solution temperatures, we observe a slow protonation reaction, i.e., [BK+2H]2++H+ [BK+3H]3+, that is regulated by trans cis isomerization of Arg1-Pro2, resulting in the Arg1- cis-Pro2- cis-Pro3-Gly4-Phe5-Ser6- cis-Pro7-Phe8-Arg9 (all- cis) configuration. Tritium 100-102 kininogen 1 Homo sapiens 97-99 30028131-3 2018 Once formed, the all- cis [BK+3H]3+ spontaneously cleaves the bond between Pro2-Pro3 with perfect specificity, a bond that is biologically resistant to cleavage by any human enzyme. Tritium 30-32 kininogen 1 Homo sapiens 27-29 25838788-3 2015 The energetic barriers between six conformations of [BK+3H]3+ range from 0.23 +-0.01 to 0.55 +-0.03 eV. Tritium 56-58 kininogen 1 Homo sapiens 53-55 25838788-6 2015 The combination of structural assignments, experimentally determined barrier heights, onset of the quasi-equilibrium region, and dissociation threshold are used to derive a semi-quantitative potential energy surface for main features of [BK+3H]3+. Tritium 241-243 kininogen 1 Homo sapiens 238-240